Importance of early and continuous use of protein restriction on the progression of adriamycin nephropathy

Página do item simplificado
dc.contributor.authorBarretti, Pasqual [UNESP]
dc.contributor.authorSoares, Vitor [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:19:47Z
dc.date.available2014-05-27T11:19:47Z
dc.date.issued1999-11-29
dc.description.abstractThree experimental protocols were carried out with the aim of evaluating the role of protein restriction on the progression of the established adriamycin-induced nephropathy, and whether the protective effect of the diet persists after the diet is discontinued. The effect of a low protein diet (LPD) was studied for 6 weeks in protocol 1, 16 weeks in protocol 2 and for 28 weeks in protocol 3. In protocol 3, one group (LL) received LPD and another (NN) was given a normal protein diet (NPD). A third group (LN) received LPD for 16 weeks and then NPD for 12 weeks and a fourth group (NL) was fed NPD for 16 weeks and then LPD for 12 weeks. In protocol I the tubulo- interstitial index (TILl) of rats on LPD (Md = 2, P25 = 0.0; P75 = 3.5) after six weeks, was smaller than that of the animals on NPD (Md = 6.0; P25 = 3.0; P75 = 8.0; p < 0.05). In protocol 2, the group taking LPD presented an area of interstitial fibrosis (IF) (Md= 0.5%, P25 0.2%; P75 = 1.9%) smaller than that of the NPD group (Md = 6.8%; P25 = 5.2%; P75 = 7.1%; P < 0.05). No significant difference in the area of glomerulosclerosis (GSA) was observed between the animals on LPD (Md = 0.0%; P25 = 0.0%, P75 = 0.0%) and NPD (Md = 0.37%; P25 = 02% P75 = 1.25%; p > 0.05). In protocol 3, the group LL showed GSA (Md = 1.3%; P25 0.6%, P75 = 2.5%) and IF (Md = 3.60/0; P25 = 1.6%; P75 = 5.9%) smaller that those of LN (GSA Md = 10.1%; P25 = 6.6%; P75 = 14.8%; IF; Md = 17.3%; P25 = 14.1%; P75 = 24,5%), NL (GSA: Md = 9.1%; P25 = 5,8%; P75 = 11.7%; IF; Md = 25.0%; P25 = 20.4%; P75 = 30%), and NN (GSA: Md = 6. 75%; P25 = 4.9%; P75 = 11.7%; IF: Md = 20.9%; P25 = 16.2%; P75 = 32.4%). In conclusion, in order to be effective, LPD must be introduced early and maintained for a long period of tune.en
dc.description.affiliationDepartment of Internal Medicine Division of Nephrology Botucatu Medical School-UNESP, Botucatu
dc.description.affiliationBotucatu Medical School Dept. of Internal Medicine Division of Nephrology, Botucatu, SP 18618-970
dc.description.affiliationUnespDepartment of Internal Medicine Division of Nephrology Botucatu Medical School-UNESP, Botucatu
dc.description.affiliationUnespBotucatu Medical School Dept. of Internal Medicine Division of Nephrology, Botucatu, SP 18618-970
dc.format.extent603-613
dc.identifierhttp://dx.doi.org/10.3109/08860229909094154
dc.identifier.citationRenal Failure, v. 21, n. 6, p. 603-613, 1999.
dc.identifier.doi10.3109/08860229909094154
dc.identifier.issn0886-022X
dc.identifier.lattes5496411983893479
dc.identifier.orcid0000-0003-4979-4836
dc.identifier.scopus2-s2.0-0032724456
dc.identifier.urihttp://hdl.handle.net/11449/65891
dc.identifier.wosWOS:000083847000003
dc.language.isoeng
dc.relation.ispartofRenal Failure
dc.relation.ispartofjcr1.440
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectAdriamycin nephropathy
dc.subjectProtein restriction
dc.subjectProteinuria
dc.subjectTubulointterstitial nephritis
dc.subjectdoxorubicin
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectcontrolled study
dc.subjectcreatinine blood level
dc.subjectdiet therapy
dc.subjectearly diagnosis
dc.subjectinterstitial nephritis
dc.subjectkidney disease
dc.subjectnephritis
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectprotein diet
dc.subjectprotein restriction
dc.subjectproteinuria
dc.subjectrat
dc.subjectAnimals
dc.subjectAntineoplastic Agents
dc.subjectDiet, Protein-Restricted
dc.subjectDietary Proteins
dc.subjectDoxorubicin
dc.subjectKidney
dc.subjectMale
dc.subjectNephritis
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectTime Factors
dc.titleImportance of early and continuous use of protein restriction on the progression of adriamycin nephropathyen
dc.typeArtigo
dcterms.licensehttp://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
unesp.author.lattes5496411983893479[1]
unesp.author.orcid0000-0003-4979-4836[1]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Coleções

Artigos - Clínica Médica - FMB